Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands

INTRODUCTION: With the approval of G12C inhibitors as the second line of treatment for KRAS G12C-mutated NSCLC, and the expanding research regarding targeting KRAS, it is key to understand the prognostic implication of KRAS G12C in the current first line of treatment. We compared overall survival (O...

Descripción completa

Detalles Bibliográficos
Autores principales: Noordhof, Anneloes L., Swart, Esther M., Damhuis, Ronald A.M., Hendriks, Lizza E.L., Kunst, Peter W.A., Aarts, Mieke J., van Geffen, Wouter H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477684/
https://www.ncbi.nlm.nih.gov/pubmed/37674812
http://dx.doi.org/10.1016/j.jtocrr.2023.100543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477684/
https://www.ncbi.nlm.nih.gov/pubmed/37674812
http://dx.doi.org/10.1016/j.jtocrr.2023.100543

Ejemplares similares